This website uses cookies

Read our Privacy policy and Terms of use for more information.

In a randomized Phase 2b trial presented at EASD in Milan last week, Lilly’s EloraTZP (eloralintide, a selective amylin agonist, given with tirzepatide) produced 23.3% estimated weight loss at 48 weeks at its top dose, eloralintide 9 mg with tirzepatide 15 mg, in adults with obesity or overweight and type 2 diabetes. Tirzepatide 15 mg alone, in the same trial, produced 14.8%. That 8.5-percentage-point gap is the strongest thing in this data set, because it comes from a comparison within one randomized trial rather than across trials.

Weight loss has generally been smaller in trials enrolling people with type 2 diabetes, which makes that gap worth attention. It comes with qualifiers. The comparison with tirzepatide was secondary and reported without confidence intervals, the data are from a press release, and 23.3% is an efficacy estimand. And people in the combination arms stopped treatment for adverse events more often than those on tirzepatide alone. More weight loss, more people stopping: that is the tension to resolve.

Clinical Takeaway
DomainKey FindingEvidence
WeightEloralintide 9 mg + tirzepatide 15 mg: −23.3% at 48 weeks vs −14.8% on tirzepatide 15 mg alone in the same randomized trial, and −3.0% on placebo, in adults with obesity or overweight and type 2 diabetes. Difference vs tirzepatide: 8.5 percentage points.Phase 2b RCT, 367 randomized; secondary comparison, no CIs reported; efficacy estimand; press release
GlucoseA1C fell 2.2 to 2.9 percentage points from a baseline of 8.1% across combinations, vs 2.4 with tirzepatide 15 mg alone.Secondary endpoint; about 37 per arm
TolerabilityGI adverse events were more frequent on the combinations. Stopping treatment for adverse events: 10.8% to 27.0% across combination arms vs 2.9% on tirzepatide alone; 16.7% on placebo.Rates not mapped to dose pairs
StatusInvestigational. Treatment-regimen estimand results not yet released. Lilly plans Phase 3 of a co-formulation by the end of 2026 using an optimized escalation schedule; whether that improves tolerability is for Phase 3 to show.Sponsor-reported

Subscribe to keep reading

This content is free, but you must be subscribed to Substance Over Noise to continue reading.

I consent to receive newsletters via email. Terms of use and Privacy policy.

Already a subscriber?Sign in.Not now